Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives

2020 ◽  
Vol 18 (6) ◽  
pp. 592-609 ◽  
Author(s):  
Eirini Kapniari ◽  
Prokopios Papadimitriou ◽  
Marianna Dalamaga ◽  
George Makavos ◽  
Stefano Piaserico ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Systemic Inflammation ◽  
Chronic Inflammatory Disease ◽  
Biologic Agents ◽  
The Body ◽  
Current Evidence ◽  
Therapeutic Implications ◽  
Underlying Mechanisms ◽  
Cv Disease ◽  
The Relationship

Psoriasis; a chronic inflammatory disease is characterized by symmetric hyperkeratotic plaques affecting any part of the body. Psoriasis is nowadays considered as a systemic inflammation linked with several comorbidities as metabolic syndrome, depression, anxiety and increased prevalence of cardiovascular (CV) disease. The hypothesis that psoriasis is an independent CV risk factor leading to atherosclerosis via inflammation is now widely accepted. Deciphering the underlying mechanisms interconnecting psoriasis and CV disease may have significant implications in treatment decisions. Accumulating evidence suggests that systematic therapies and recently introduced biologic agents, that control psoriasis by suppressing the chronic and systemic inflammation, may alter the progression of CV disease. We herein attempt a review of current evidence analysing the relationship between psoriasis and CV comorbidities, comment on the mechanisms underlying this association and investigate the consequences for the management of psoriasis.

scholarly journals Patients with Ankylosing Spondylitis and Low Disease Activity because of Anti-TNF-Alpha Therapy Have Higher TRAIL Levels Than Controls: A Potential Compensatory Effect

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Fernanda Genre ◽  
Raquel López-Mejías ◽  
Javier Rueda-Gotor ◽  
José A. Miranda-Filloy ◽  
Begoña Ubilla ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Systemic Inflammation ◽  
Inverse Correlation ◽  
Chronic Inflammatory Disease ◽  
Compensatory Mechanism ◽  
Infliximab Infusion ◽  
Potential Biomarker ◽  
Marginal Association ◽  
Cv Disease

Objective. TRAIL is a potential biomarker of cardiovascular (CV) disease. Ankylosing spondylitis (AS) is a chronic inflammatory disease associated with metabolic syndrome (MeS) and accelerated atherosclerosis. We assessed whether disease activity, systemic inflammation, and MeS features were associated with circulating TRAIL levels in AS patients undergoing TNF-αantagonist infliximab therapy and if infliximab infusion modified TRAIL levels.Methods. We measured TRAIL serum levels in 30 nondiabetic AS patients without CV disease undergoing anti-TNF-αtherapy, immediately before and after an infliximab infusion, and in 48 matched controls. Correlations of TRAIL levels with disease activity, systemic inflammation and MeS features, adipokines, and biomarkers of endothelial activation were evaluated. Changes in TRAIL levels following anti-TNF-αinfusion were analyzed.Results. TRAIL levels were higher in AS patients than controls. TRAIL levels displayed an inverse correlation with total and LDL cholesterol. We observed an inverse correlation with QUICKI and a marginal association with HOMA-IR. We also found an inverse correlation with resistin and a marginal association with apelin and OPN. Anti-TNF-αinfusion did not change TRAIL levels after 120′.Conclusion. Elevated TRAIL levels in AS patients may be the result of a compensatory mechanism to reduce CV risk in these patients.

scholarly journals Advanced Research of Abdominal Aortic Aneurysms on Metabolism

2021 ◽  
Vol 8 ◽  
Author(s):  
Yangfeng Hou ◽  
Wenjun Guo ◽  
Tianfei Fan ◽  
Bolun Li ◽  
Weipeng Ge ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Abdominal Aortic Aneurysm ◽  
Theoretical Basis ◽  
Abdominal Aortic Aneurysms ◽  
The Body ◽  
Aortic Aneurysms ◽  
Research Progress ◽  
Risk Of Death ◽  
Abdominal Aortic ◽  
The Relationship

Abdominal aortic aneurysm (AAA) is a cardiovascular disease with a high risk of death, seriously threatening the life and health of people. The specific pathogenesis of AAA is still not fully understood. In recent years, researchers have found that amino acid, lipid, and carbohydrate metabolism disorders play important roles in the occurrence and development of AAA. This review is aimed to summarize the latest research progress of the relationship between AAA progression and body metabolism. The body metabolism is closely related to the occurrence and development of AAA. It is necessary to further investigate the pathogenesis of AAA from the perspective of metabolism to provide theoretical basis for AAA diagnosis and drug development.

scholarly journals The Interaction of C - Reactive Protein, Bisphenol A, & Cardiovascular Disease: A Demographical Analysis

2016 ◽  
Vol 9 (3) ◽  
pp. 63 ◽  
Author(s):  
Hassan Naji
Keyword(s):  
Cardiovascular Disease ◽  
Bisphenol A ◽  
Quantitative Research ◽  
The Body ◽  
Spearman Correlation ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
The Impact ◽  
The Relationship

<p><strong>OBJECTIVE: </strong>The main objective of the study was to investigate the role of C-reactive protein on the relationship between Bisphenol A &amp; Cardiovascular Disease, where the C-reactive protein has been taken as a moderating variable.</p><p><strong>METHODS: </strong>Quantitative research design has been incorporated for evaluating the role of C-reactive protein. Similarly, non-parametric Spearman correlation test has been conducted to assess the relationship between BPA and CVD. The data was taken out from the National Health and Nutrition Examination Survey (NHANES), which was collected in the year 2009-2010.</p><p><strong>RESULTS: </strong>The impact of urinary Bisphenol A on serum C-reactive protein was found statistically significant according to the Spearman correlation coefficient, <em>r</em>s<em>= </em>.06, <em>p </em>= .015. The scatter plots found that there is no relationship between the two variables; this observation held true after filtering the outliers from the plot.</p><p><strong>CONCLUSION:</strong> The results might have positive change by contributing to the body of knowledge on bisphenol A and by rising scientific examination of substances used by the people in the daily life. Further research to identify other possible causes of CVD and elevation of CRP is recommended.</p>

Exploring the seasonal drivers of varicella zoster transmission and reactivation

2021 ◽  
Author(s):  
Kevin M Bakker ◽  
Marisa C Eisenberg ◽  
Robert Woods ◽  
Micaela E Martinez
Keyword(s):  
Population Level ◽  
The Body ◽  
Viral Reactivation ◽  
Small Scale ◽  
Disease Treatment ◽  
Seasonal Incidence ◽  
Varicella Zoster ◽  
Underlying Mechanisms ◽  
And Control ◽  
The Relationship

Abstract Varicella zoster virus (VZV) is a herpesvirus that causes chickenpox and shingles. The biological mechanisms underpinning the multi-decadal latency of VZV in the body and subsequent viral reactivation—which occurs in approximately 30% of individuals—are largely unknown. Because chickenpox and shingles are endemic worldwide, understanding the relationship between VZV transmission and reactivation is important for informing disease treatment and control. While chickenpox is a vaccine-preventable childhood disease with a rich legacy of research, shingles is not a notifiable disease in most countries. To date, population-level studies of shingles have had to rely on small-scale hospital or community-level datasets. Here, we examined chickenpox and shingles notifications from Thailand and found strong seasonal incidence in both diseases, with a 3-month lag between peak chickenpox transmission season and peak shingles reactivation. We tested and fit 14 mathematical models examining the biological driversof chickenpox and shingles over an 8-year period to estimate rates of VZV transmission, reactivation, and immunity boosting, wherein re-exposure to VZV boosts VZV-specific immunity to reinforce protection against shingles. The models suggested the seasonal cycles of chickenpox and shingles have different underlying mechanisms, with ultraviolet radiation (UV) being correlated with shingles reactivation.

scholarly journals Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity

2022 ◽  
Vol 8 ◽  
Author(s):  
Dong-Woo Kang ◽  
Rebekah L. Wilson ◽  
Cami N. Christopher ◽  
Amber J. Normann ◽  
Oscar Barnes ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Premature Mortality ◽  
Therapeutic Modality ◽  
Current Evidence ◽  
Pharmacological Intervention ◽  
Clinical Approach ◽  
Lifestyle Risk Factors ◽  
Lifestyle Risk ◽  
Underlying Mechanisms

Anthracyclines are one of the most effective chemotherapy agents and have revolutionized cancer therapy. However, anthracyclines can induce cardiac injuries through ‘multiple-hits', a series of cardiovascular insults coupled with lifestyle risk factors, which increase the risk of developing short- and long-term cardiac dysfunction and cardiovascular disease that potentially lead to premature mortality following cancer remission. Therefore, the management of anthracycline-induced cardiotoxicity is a serious unmet clinical need. Exercise therapy, as a non-pharmacological intervention, stimulates numerous biochemical and physiologic adaptations, including cardioprotective effects, through the cardiovascular system and cardiac muscles, where exercise has been proposed to be an effective clinical approach that can protect or reverse the cardiotoxicity from anthracyclines. Many preclinical and clinical trials demonstrate the potential impacts of exercise on cardiotoxicity; however, the underlying mechanisms as well as how to implement exercise in clinical settings to improve or protect against long-term cardiovascular disease outcomes are not clearly defined. In this review, we summarize the current evidence in the field of “exercise cardio-oncology” and emphasize the utilization of exercise to prevent and manage anthracycline-induced cardiotoxicities across high-risk and vulnerable populations diagnosed with cancer.

scholarly journals Gut Microbiota: A Novel Regulator of Cardiovascular Disease and Key Factor in the Therapeutic Effects of Flavonoids

2021 ◽  
Vol 12 ◽  
Author(s):  
Qinyu Li ◽  
Bing Gao ◽  
Bateer Siqin ◽  
Qian He ◽  
Ru Zhang ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Cardiovascular Disease ◽  
Gut Microbiota ◽  
The Body ◽  
Therapeutic Effects ◽  
Protective Effects ◽  
Key Factor ◽  
The Relationship ◽  
Infarction Heart

Cardiovascular disease is the main cause of death worldwide, and traditional cardiovascular risk factors cannot fully explain the occurrence of the disease. In recent years, the relationship between gut microbiota and its metabolites and cardiovascular disease has been a hot study topic. The changes in gut microbiota and its metabolites are related to the occurrence and development of atherosclerosis, myocardial infarction, heart failure, and hypertension. The mechanisms by which gut microbiota and its metabolites influence cardiovascular disease have been reported, although not comprehensively. Additionally, following ingestion, flavonoids are decomposed into phenolic acids that are more easily absorbed by the body after being processed by enzymes produced by intestinal microorganisms, which increases flavonoid bioavailability and activity, consequently affecting the onset of cardiovascular disease. However, flavonoids can also inhibit the growth of harmful microorganisms, promote the proliferation of beneficial microorganisms, and maintain the balance of gut microbiota. Hence, it is important to study the relationship between gut microbiota and flavonoids to elucidate the protective effects of flavonoids in cardiovascular diseases. This article will review the role and mechanism of gut microbiota and its metabolites in the occurrence and development of atherosclerosis, myocardial infarction, heart failure, and hypertension. It also discusses the potential value of flavonoids in the prevention and treatment of cardiovascular disease following their transformation through gut microbiota metabolism.

scholarly journals Migraine patients should be cautiously followed for risk factors leading to cardiovascular disease

2013 ◽  
Vol 71 (2) ◽  
pp. 119-124 ◽  
Author(s):  
Ivan Rocha Ferreira da Silva ◽  
Gabriel R. de Freitas
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Ischemic Stroke ◽  
Cardiovascular Events ◽  
Causal Relation ◽  
Current Evidence ◽  
Evidence Based ◽  
Compelling Evidence ◽  
Therapeutic Implications

Migraine and ischemic strokes are two of the most prevalent diseases worldwide. Besides having a coincident symptomatology, for long researchers have been searching for a possible causal relation between these diseases. Current evidence based on data suggest that patients with aura migraine could have a doubled risk of developing an ischemic stroke, when compared to the rest of the population. At the same time, migraine sufferers apparently have higher incidences of risk factors for cardiovascular events. The aim of this review was not only to dissect some of the more compelling evidence based on data regarding this association, but also to discuss the possible clinical and therapeutic implications.

scholarly journals Mechanisms of Melatonin in Obesity: A Review

2021 ◽  
Vol 23 (1) ◽  
pp. 218
Author(s):  
Qingyun Guan ◽  
Zixu Wang ◽  
Jing Cao ◽  
Yulan Dong ◽  
Yaoxing Chen
Keyword(s):  
Current Knowledge ◽  
Public Health Problem ◽  
The Body ◽  
Global Public Health ◽  
Opioidergic System ◽  
Glucose And Lipid Metabolism ◽  
Underlying Mechanisms ◽  
The Relationship ◽  
Global Public Health Problem

Obesity and its complications have become a prominent global public health problem that severely threatens human health. Melatonin, originally known as an effective antioxidant, is an endogenous hormone found throughout the body that serves various physiological functions. In recent decades, increasing attention has been paid to its unique function in regulating energy metabolism, especially in glucose and lipid metabolism. Accumulating evidence has established the relationship between melatonin and obesity; nevertheless, not all preclinical and clinical evidence indicates the anti-obesity effect of melatonin, which makes it remain to conclude the clinical effect of melatonin in the fight against obesity. In this review, we have summarized the current knowledge of melatonin in regulating obesity-related symptoms, with emphasis on its underlying mechanisms. The role of melatonin in regulating the lipid profile, adipose tissue, oxidative stress, and inflammation, as well as the interactions of melatonin with the circadian rhythm, gut microbiota, sleep disorder, as well as the α7nAChR, the opioidergic system, and exosomes, make melatonin a promising agent to open new avenues in the intervention of obesity.

Abstract 17: The Association Between Erythrocyte n-3 Polyunsaturated Fatty Acids (n-3 PUFAs) Content and Inflammation in Male Patients With Peripheral Artery Disease (PAD)

2013 ◽  
Vol 33 (suppl_1) ◽  
Author(s):  
Marlene Grenon ◽  
Christopher D Owens ◽  
Hugh Alley ◽  
Karen Chong ◽  
Eric Vittinghoff ◽  
...  
Keyword(s):  
Cohort Study ◽  
Systemic Inflammation ◽  
Smoking Status ◽  
Ankle Brachial Index ◽  
The Body ◽  
Omega 3 ◽  
Male Population ◽  
Negatively Associated ◽  
Tnf Α ◽  
The Relationship

Objectives Dietary intake of n-3 PUFAs has been associated with cardiovascular disease, though the relationship to PAD is unclear. PAD patients have an increased burden of systemic inflammation. In a cross-sectional PAD cohort study, we evaluated the relationship between n-3 PUFAs content of red blood cells (omega-3 index) and biomarkers of systemic inflammation. Methods This was a prospective cohort study of patients (n=83) presenting to vascular surgery clinic for evaluation of PAD. The omega-3 index was measured using gas chromatography and inflammatory markers (hsCRP, IL-6, TNF-α and ICAM-1) via ELISA kits. We used linear regression to evaluate the independent association between the omega-3 index and inflammation. Results 70 patients had PAD while 13 were found to have a normal ankle-brachial index (ABI). Mean (±SD) age was 67 ± 7 years. Mean ABI was 0.85 ± 0.23. The omega-3 index decreased across defined AHA hsCRP categories (Figure 1, p=0.04). One percentage point decrease in the omega-3 index was associated with increases in CRP (14%, 95% CI 0, 25, p=0.04), IL6 (8%, 95% CI 1, 15, p=0.02) and possibly ICAM-1 (4%, 95% CI -1, 12, p=0.13), but not TNF-α. After adjusting for age, race, HDL, smoking status, ABI and the body-mass index, the omega-3 index remained significantly (negatively) associated with systemic inflammation as measured by hsCRP in a male population at risk or suffering from PAD (p=0.05). Conclusions In a contemporary cohort of patients with PAD, the omega-3 index was negatively associated with biomarkers of inflammation. Our findings suggest a rationale for future studies of dietary manipulation of omega-3 index to reduce inflammation in patients with PAD.

scholarly journals Vitamin D and Cardiovascular Disease: Current Evidence and Future Perspectives

Nutrients ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 3603
Author(s):  
Nicola Cosentino ◽  
Jeness Campodonico ◽  
Valentina Milazzo ◽  
Monica De Metrio ◽  
Marta Brambilla ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Close Association ◽  
Age Groups ◽  
Current Evidence ◽  
Prognostic Impact ◽  
Therapeutic Implications ◽  
Vitamin D Levels ◽  
Patients At Risk

Vitamin D deficiency is a prevalent condition, occurring in about 30–50% of the population, observed across all ethnicities and among all age groups. Besides the established role of vitamin D in calcium homeostasis, its deficiency is emerging as a new risk factor for cardiovascular disease (CVD). In particular, several epidemiological and clinical studies have reported a close association between low vitamin D levels and major CVDs, such as coronary artery disease, heart failure, and atrial fibrillation. Moreover, in all these clinical settings, vitamin deficiency seems to predispose to increased morbidity, mortality, and recurrent cardiovascular events. Despite this growing evidence, interventional trials with supplementation of vitamin D in patients at risk of or with established CVD are still controversial. In this review, we aimed to summarize the currently available evidence supporting the link between vitamin D deficiency and major CVDs in terms of its prevalence, clinical relevance, prognostic impact, and potential therapeutic implications.

Sign in / Sign up

Export Citation Format

Share Document